Outi M. H. Salo-Ahen
Outi M. H. Salo-Ahen
Adjunct Professor (Docent), Senior University Lecturer, Åbo Akademi University
Vahvistettu sähköpostiosoite verkkotunnuksessa
Computational approaches to identifying and characterizing protein binding sites for ligand design
S Henrich, OMH Salo‐Ahen, B Huang, FF Rippmann, G Cruciani, ...
Journal of Molecular Recognition: An Interdisciplinary Journal 23 (2), 209-219, 2010
Molecular dynamics simulations in drug discovery and pharmaceutical development
OMH Salo-Ahen, I Alanko, R Bhadane, AMJJ Bonvin, RV Honorato, ...
Processes 9 (1), 71, 2020
Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes
SM Saario, OMH Salo, T Nevalainen, A Poso, JT Laitinen, T Järvinen, ...
Chemistry & biology 12 (6), 649-656, 2005
Towards peptide vaccines against Zika virus: Immunoinformatics combined with molecular dynamics simulations to predict antigenic epitopes of Zika viral proteins
M Usman Mirza, S Rafique, A Ali, M Munir, N Ikram, A Manan, ...
Scientific reports 6 (1), 37313, 2016
Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CLpro
MA Alamri, M Tahir Ul Qamar, MU Mirza, R Bhadane, SM Alqahtani, ...
Journal of Biomolecular Structure and Dynamics 39 (13), 4936-4948, 2021
Protein–protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase
D Cardinale, G Guaitoli, D Tondi, R Luciani, S Henrich, OMH Salo-Ahen, ...
Proceedings of the National Academy of Sciences 108 (34), E542-E549, 2011
Development of a 3D model for the human cannabinoid CB1 receptor
OMH Salo, M Lahtela-Kakkonen, J Gynther, T Järvinen, A Poso
Journal of medicinal chemistry 47 (12), 3048-3057, 2004
Targeting the cannabinoid CB2 receptor: mutations, modeling and development of CB2 selective ligands
KH Raitio, OMH Salo, T Nevalainen, A Poso, T Jarvinen
Current medicinal chemistry 12 (10), 1217-1237, 2005
CB receptor ligands from plants
R Bauer, K Woelkart, OMH Salo-Ahen
Current Topics in Medicinal Chemistry 8 (3), 173-186, 2008
Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor
OMH Salo, KH Raitio, JR Savinainen, T Nevalainen, M Lahtela-Kakkonen, ...
Journal of medicinal chemistry 48 (23), 7166-7171, 2005
Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system
SM Saario, A Poso, RO Juvonen, T Järvinen, OMH Salo-Ahen
Journal of medicinal chemistry 49 (15), 4650-4656, 2006
Novel approaches for targeting thymidylate synthase to overcome the resistance and toxicity of anticancer drugs
D Garg, S Henrich, OMH Salo-Ahen, H Myllykallio, MP Costi, RC Wade
Journal of medicinal chemistry 53 (18), 6539-6549, 2010
Antigenic Peptide Prediction From E6 and E7 Oncoproteins of HPV Types 16 and 18 for Therapeutic Vaccine Design Using Immunoinformatics and MD Simulation Analysis
B Jabbar, S Rafique, OMH Salo-Ahen, A Ali, M Munir, M Idrees, MU Mirza, ...
Frontiers in Immunology (Viral Immunology) 9 (Article 3000), 10.3389/fimmu …, 2018
Identification of WIN55212‐3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor
JR Savinainen, T Kokkola, OMH Salo, A Poso, T Järvinen, JT Laitinen
British journal of pharmacology 145 (5), 636-645, 2005
Homodimeric enzymes as drug targets
D Cardinale, OMH Salo-Ahen, S Ferrari, G Ponterini, G Cruciani, ...
Current medicinal chemistry 17 (9), 826-846, 2010
Dynamics of CYP51: implications for function and inhibitor design
X Yu, V Cojocaru, G Mustafa, OMH Salo‐Ahen, GI Lepesheva, RC Wade
Journal of Molecular Recognition 28 (2), 59-73, 2015
Tailored Approaches in Drug Development and Diagnostics: From Molecular Design to Biological Model Systems
C Sahlgren, A Meinander, H Zhang, F Cheng, M Preis, C Xu, TA Salminen, ...
Advanced healthcare materials, 2017
Inhibition of oncogenic kinases: an in vitro validated computational approach identified potential multi-target anticancer compounds
N Ikram, MU Mirza, M Vanmeert, M Froeyen, OMH Salo-Ahen, M Tahir, ...
Biomolecules 9 (4), 124, 2019
Hotspots in an obligate homodimeric anticancer target. Structural and functional effects of interfacial mutations in human thymidylate synthase
OMH Salo-Ahen, A Tochowicz, C Pozzi, D Cardinale, S Ferrari, Y Boum, ...
Journal of medicinal chemistry 58 (8), 3572-3581, 2015
The functional role of cysteines adjacent to the NRY motif of the human MT1 melatonin receptor
T Kokkola, OMH Salo, A Poso, JT Laitinen
Journal of pineal research 39 (1), 1-11, 2005
Järjestelmä ei voi suorittaa toimenpidettä nyt. Yritä myöhemmin uudelleen.
Artikkelit 1–20